News Coverage
-
Georgia men undergo risky surgery in battle against ALS
FOX Medical Team Reporter Beth Galvin continues her coverage of Neuralstem’s ongoing NSI-566/ALS Phase II trial with a patient perspective piece featuring Ted Harada and John Conley, both treated during Phase I at Emory University Hospital.
-
Risky surgery provides hope for ALS patients
FOX Medical Team’s Beth Galvin reports on Neuralstem’s first NSI-566/ALS Phase II patient, Kathy Lingle, two months post-treatment of ten injections of a total of two million cells at Emory University Hospital in this sweeping feature segment that includes graphic footage of the surgery that “is almost becoming routine.” Site Principal Investigator Dr. Jonathan Glass and Co-Investigator and Neurosurgeon Dr. Nicholas Boulis share insights on exposing “the riskiest real estate in the body,” the cervical spinal cord, “the most important and the most dangerous” in patients’ quest for a cure that Beth Galvin says, “all comes down to one word: hope.”
-
Cash, Catalysts And Charisma Should Drive Neuralstem
A comprehensive overview of the year ahead for Neuralstem’s ongoing and upcoming cell therapy and neurogenic small molecule clinical trials.
-
Decreasing Progression, Increasing Function
Chairman and CSO Dr. Karl Johe and Principal Investigator Dr. Eva Feldman are quoted in this article on Neuralstem’s NSI-566/ALS program that looks ahead to Phase III, overviews Phase II and explores Phase I findings, following Dr. Feldman’s presentation of data at the 2013 Canadian Neurological Sciences Federation Congress.
-
A Better Pill To Swallow
A writer who has struggled with depression pens a feature story brimming with new insights about the condition and Neuralstem’s work to create a “potential wonder drug aimed specifically at rebuilding neurons in the hippocampus”: NSI-189. Insights include the initial mission, experiences and passions that brought Dr. Karl Johe and Richard Garr together to form a company that would set out to achieve novel neurogenic and cell therapy treatments to address huge unmet medical needs. The article appears on the eve of the expected completion and initial data of Neuralstem’s NSI-189/major depressive disorder Phase Ib trial this quarter.
